Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
Authors:
- Mark R. LitzowMLMark R. Litzow
- Zhuoxin SunZSZhuoxin Sun
- Ryan J. MattisonRMRyan J. Mattison
- Elisabeth M. PaiettaEPElisabeth M. Paietta
- Kathryn G. RobertsKRKathryn G. Roberts
- Yanming ZhangYZYanming Zhang
- Janis RacevskisJRJanis Racevskis
- Hillard M. LazarusHLHillard M. Lazarus
- Jacob M. RoweJRJacob M. Rowe
- Daniel A. ArberDADaniel A. Arber
- Matthew J. WieduwiltMWMatthew J. Wieduwilt
- Michaela LiedtkeMLMichaela Liedtke
Top Cited Papers
- 25 July 2024
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 391 (4) , 320-333
Abstract
No abstract availableFunding Information
- ECOG-ACRIN Cancer Research Group (U10CA180820, U10CA180794, U10CA180821, U10CA180888)
This publication has 21 references indexed in Scilit:
- Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trialThe Lancet Haematology, 2022
- Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high‐risk first relapse B‐cell precursor acute lymphoblastic leukemiaPediatric Blood & Cancer, 2022
- Measurable Residual Disease Detection in B‐Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) MethodCurrent Protocols, 2022
- Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic LeukemiaJAMA, 2021
- Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic LeukemiaJAMA, 2021
- Acute lymphoblastic leukaemiaThe Lancet, 2020
- Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic LeukemiaJAMA Oncology, 2017
- Rituximab in B-Lineage Adult Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2016
- Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemiaLeukemia, 2014
- Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysisLeukemia, 2011